In South Korea, where a few powerful families control most industries and millennials are struggling with job prospects, getting rich quickly isn’t easy.
So when drug maker SK Biopharmaceuticals Co., a unit of one of the nation’s largest conglomerates, SK Group, went public, it stood out not only for the level of wealth creation given to a portion of its workforce, but for how quickly it happened. Some also viewed it as a sign that things may be starting to change in Korea.
